{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T13:50:42Z","timestamp":1766065842507},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T00:00:00Z","timestamp":1236038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Prophylactic infusion of factor concentrates is a safe, effective intervention for preventing arthropathy in patients with haemophilia; on\u2010demand treatment is insufficient to prevent the orthopaedic complications and subsequent haemophilic arthropathy that stem from recurrent joint haemorrhages. The usefulness of prophylaxis in haemophilia patients without inhibitors suggests that patients with haemophilia and inhibitors could derive similar benefits. In patients with haemophilia and high\u2010titre (&gt;5\u2003BU\u2003mL<jats:sup>\u22121<\/jats:sup>) inhibitors, bleeding episodes are treated with bypassing agents such as activated prothrombin complex concentrates (APCCs) and recombinant activated factor VII (rFVIIa, N<jats:sc>ovo<\/jats:sc>S<jats:sc>even<\/jats:sc><jats:sup>\u00ae<\/jats:sup>; Novo Nordisk A\/S, Bagsvaerd, Denmark). It is possible to administer bypassing therapy regularly to prevent haemorrhages, with the goal of limiting arthropathy and serious life\u2010 and limb\u2010threatening bleeding. The data evaluating the efficacy and safety of this approach in patients with inhibitors are limited, consisting of results from one prospective trial and retrospective case reports. This report describes our experience with the prophylactic use of the APCC Factor Eight Inhibitor Bypassing Activity, Anti\u2010Inhibitor Coagulant Complex, Vapor Heated (FEIBA\u2122; Baxter AG, Vienna, Austria). Data from patients at one treatment centre were retrospectively evaluated. Case records of six patients with haemophilia A or B and high\u2010titre inhibitors were identified. When APCC was administered regularly, most patients exhibited a reduction in the numbers of haemorrhages, an improvement in orthopaedic status, and an improvement in quality of life. Prophylaxis with APCC can reduce haemorrhages and halt further joint deterioration in patients with haemophilia and inhibitors.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.01980.x","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T01:57:43Z","timestamp":1236131863000},"page":"733-742","source":"Crossref","is-referenced-by-count":38,"title":["The benefits of prophylactic treatment with APCC in patients with haemophilia and high\u2010titre inhibitors: a retrospective case series"],"prefix":"10.1111","volume":"15","author":[{"given":"L. A.","family":"VALENTINO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00630.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02580.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01533.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1457"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.6.e105"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1355-0691.2004.00876.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00815.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"e_1_2_6_12_2","volume-title":"MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor to Prevent Bleeding)","year":"2006"},{"key":"e_1_2_6_13_2","volume-title":"Guidelines for the Management of Hemophilia","year":"2005"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20162"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01442.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00626.x"},{"issue":"3","key":"e_1_2_6_17_2","first-page":"113","article-title":"Evaluation of FEIBA for prophylaxis in patients with inhibitors","volume":"10","author":"Ewenstein B","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.006004294.x"},{"key":"e_1_2_6_19_2","first-page":"265a","article-title":"Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long\u2010term prophylaxis in patients with high\u2010responding inhibitors","volume":"96","author":"Kreuz W","year":"2000","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_20_2","article-title":"Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with Factor Eight Inhibitor Bypassing Activity, Vapor Heated (FEIBA VH)","volume":"3","author":"Ewing N","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"e_1_2_6_21_2","article-title":"FEIBA prophylaxis in hemophilia A patient with inhibitors decreases bleeding episodes, improves joint function and enhance quality of life","volume":"12","author":"Cheng S","year":"2006","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_6_22_2","article-title":"Can long\u2010term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitor?","volume":"12","author":"Lambert T","year":"2006","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_6_23_2","article-title":"Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis","volume":"5","author":"Ewing NP","year":"2007","journal-title":"J Thromb Haemost"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"issue":"1","key":"e_1_2_6_25_2","article-title":"Efficacy and safety of FEIBA prophylaxis in a patient with hemophilia B and high\u2010titer inhibitor","volume":"3","author":"Valentino LA","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"e_1_2_6_26_2","first-page":"115","article-title":"FEIBA VH prophylaxis in hemophilia A patients with inhibitors results in 95% reduction in bleeding episodes","volume":"10","author":"Valentino LA","year":"2004","journal-title":"Haemophilia"},{"issue":"3","key":"e_1_2_6_27_2","first-page":"3","article-title":"Prophylaxis: musculoskeletal evaluation","volume":"30","author":"Gilbert MS","year":"1993","journal-title":"Semin Hematol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00640.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(79)90096-1"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2337"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440413.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2003.00870.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20204"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01654.x"},{"key":"e_1_2_6_36_2","first-page":"251","article-title":"Long\u2010term therapy and on\u2010demand treatment of children and adolescents with severe haemophilia A: 12 years of experience","volume":"22","author":"Brackmann HH","year":"1992","journal-title":"Haemostasis"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470209"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.420960.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00771.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.6.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01312.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.01980.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.01980.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:07:15Z","timestamp":1697242035000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.01980.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,21]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1111\/j.1365-2516.2009.01980.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.01980.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,21]]}}}